Clinical trials
Microsatellite Stable Colorectal Cancer clinical trials
Below are recruiting microsatellite stable colorectal cancer clinical trials, each written for real people, not researchers. We’re tracking 74 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07735624RecruitingPhase 2
Immunotherapy before surgery for early rectal cancer
This trial tests a combination of two immunotherapy drugs (botensilimab and balstilimab) given before surgery for early-stage rectal cancer that is MSS/pMMR. The goal is to see if this treatment can shrink the tumor and improve outcomes compared to standard care.
Boston, MassachusettsAges 18 years+ - NCT07147231RecruitingPhase 1/Phase 2
Pidnarulex plus cemiplimab for MSS colorectal cancer
This trial tests two drugs together: pidnarulex (a targeted therapy) and cemiplimab (an immunotherapy that helps your immune system fight cancer). It is for people with advanced colorectal cancer that is microsatellite stable (MSS) and has not responded to current treatments, especially if their tumor has a MYC or FBXW7 change.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06589440RecruitingPhase 2
Study of SR-8541A plus two immunotherapies for advanced colorectal cancer
This trial tests a new drug combination (SR-8541A, botensilimab, and balstilimab) for people with a specific type of metastatic colorectal cancer that is not MSI-high. It aims to see if this combination can help when other treatments have stopped working.
Morristown, New JerseyAges 18 years+ - NCT06696768RecruitingPhase 1
New drug plus standard chemotherapy for advanced colorectal cancer
This trial combines a new experimental drug (emavusertib) with standard chemotherapy (FOLFOX plus bevacizumab) for people with stage IV colorectal cancer who have not yet received chemotherapy. The goal is to see if the combination is safe and effective, potentially offering a new first-line treatment option.
Gainesville, FloridaAges 18 years+ - NCT07722494RecruitingPhase 3
Investigational drug plus bevacizumab for advanced colorectal cancer
This trial tests a new drug combined with a standard treatment for advanced colorectal cancer that has not responded to earlier therapies. It aims to see if the combination can help slow the cancer's growth.
Wuhan, WuhanAges 18 years+ - NCT07284849RecruitingPhase 3
Testing a new drug combo for advanced colorectal cancer
This trial tests whether adding an experimental drug (INCA33890) to standard chemotherapy and bevacizumab helps people with a certain type of advanced colorectal cancer. It is for those whose cancer has spread and has not been treated yet with systemic therapy.
Mobile, AlabamaAges 18 years+ - NCT06841159RecruitingPhase 2
Personalized radiation plus immunotherapy and chemo for metastatic colorectal cancer
This trial tests a new combination of ultra-precise radiation therapy, immunotherapy, chemotherapy, and targeted therapy for people with metastatic colorectal cancer that has a normal DNA mismatch repair system. The goal is to see if this personalized approach can better control the cancer and improve outcomes.
ShanghaiAges 18–75 - NCT06282445RecruitingPhase 2
Combination therapy for first-line metastatic colorectal cancer
This trial tests whether adding the immunotherapy drug adebrelimab to standard chemotherapy plus bevacizumab can help people with a specific type of metastatic colorectal cancer that cannot be removed by surgery. It is for patients whose tumors are microsatellite stable (MSS) or have normal mismatch repair (pMMR).
Jinhua, ZhejiangAges 18–75 - NCT05963490RecruitingPhase 2
Regorafenib with or without targeted immunotherapy and radiation for spread colon cancer
This Phase 2 study tests whether taking regorafenib alone or with immunotherapy (toripalimab) and a lower-dose radiation plan can better control metastatic colon or rectal cancer that has MSS/pMMR. It may help by combining cancer-blocking medicine with immune activation and focused radiation to metastatic spots.
ShanghaiAges 18–70 - NCT05585814RecruitingPhase 2
New chemo plus immunotherapy before rectal surgery
This trial tests a combination of chemo, a medicine that blocks blood vessel growth, and an immune checkpoint drug given before rectal cancer surgery. It’s for people with locally advanced rectal cancer without distant spread, to try to shrink the tumor and improve surgical results.
ShanghaiAges 18–75 - NCT07527858RecruitingPhase 2
Study of Denikitug with immunotherapy or chemotherapy for advanced colorectal cancer
This trial tests a new drug called denikitug, given alone or combined with other cancer treatments, for patients with advanced colorectal cancer that hasn't responded to previous treatments. The goal is to help people whose cancer has a specific genetic profile (MSS) that doesn't respond well to standard immunotherapy alone.
North Haven, ConnecticutAges 18 years+ - NCT06550453RecruitingPhase 4
Immunotherapy plus chemo before surgery for RAS-mutated colorectal cancer
This trial tests a combination of immunotherapy (pembrolizumab) plus targeted therapy (bevacizumab) and chemotherapy (CapeOX) given before surgery for a specific type of locally advanced colorectal cancer. It is designed for patients whose tumors have a RAS mutation, are BRAF normal, and are microsatellite stable.
Xi'an, ShaanxiAges 18 years+ - NCT06525428RecruitingPhase 2
Adding radiation and immunotherapy to standard care for advanced colorectal cancer
This trial is testing a combination of standard chemotherapy, radiation therapy, and an immunotherapy drug (toripalimab) for people with metastatic colorectal cancer. It aims to see if adding radiation therapy and immunotherapy can help shrink tumors and improve outcomes.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07446322RecruitingPhase 2
Study of a new drug plus standard chemo for advanced colorectal cancer
This trial tests if adding the experimental drug pelareorep to standard chemotherapy (FOLFIRI) and bevacizumab can help people with a specific type of advanced colorectal cancer that has a RAS mutation and is not caused by high microsatellite instability. You may be able to join if you've already tried one type of chemotherapy and it stopped working or you couldn't tolerate it.
Homewood, AlabamaAges 18 years+ - NCT05919264RecruitingPhase 1/Phase 2
FOG-001 for advanced solid tumors with certain gene changes
This trial tests a new drug, FOG-001, alone or with other treatments, for people with advanced solid tumors that have specific changes in the WNT pathway genes. It aims to see if the drug can shrink tumors or slow their growth.
Phoenix, ArizonaAges 18 years+ - NCT06047379RecruitingPhase 1/Phase 2
Testing NEO212 for brain tumors and metastases
This trial tests a new drug called NEO212 for people with certain brain tumors (like astrocytoma or glioblastoma) or cancer that has spread to the brain from other parts of the body. The goal is to see if it is safe and if it can help shrink or control the tumors.
Beverly Hills, CaliforniaAges 18 years+ - NCT04689347RecruitingPhase 1/Phase 2
New chemotherapy and targeted drug for a specific colon cancer type
This trial tests a combination of chemotherapy (5-FU/LV, irinotecan, and temozolomide) plus bevacizumab in metastatic colon or rectal cancer. It focuses on tumors with an “MGMT silenced” pattern (MGMT gene turned off), which may make some cancers more responsive to these medicines.
Milan, MilanAges 18–75 - NCT04895709RecruitingPhase 1/Phase 2
Testing a new cancer drug for advanced solid tumors
This early-phase trial tests how well a new drug (BMS-986340) works alone and combined with other treatments in people with advanced solid tumors that have progressed despite standard care. It also studies tumor samples to look for biomarkers that may predict who benefits.
Clovis, CaliforniaAges 18 years+ - NCT05691491RecruitingPhase 1/Phase 2
Temozolomide plus M1774 for advanced metastatic cancers
This Phase 1/2 trial tests a combination of temozolomide and M1774 to see how safe it is and whether it can help shrink advanced cancers that have spread. It focuses on certain tumor types and specific biomarker results, and it may be an option if standard treatments have been tried or aren’t possible.
Irvine, CaliforniaAges 18 years+ - NCT05768503RecruitingPhase 3
Test new drugs after colorectal cancer chemotherapy
This Phase 3 trial compares a new treatment combination (chidamide plus sintilimab plus bevacizumab) versus the standard second-line chemotherapy (FOLFIRI plus bevacizumab) for advanced colorectal cancer that is microsatellite stable/low. It aims to see which treatment works better and is safer for people whose cancer grew after first-line oxaliplatin-based therapy.
Hefei, AnhuiAges 18–75 - NCT05771181RecruitingPhase 2
Test vitamin E plus two cancer drugs for metastatic colon cancer
This trial tests whether adding vitamin E to two cancer medicines (fruityquintinib and tislelizumab) can work better in people with metastatic colorectal cancer that is mismatch-repair stable (MSS). It may help if your cancer has grown despite standard treatment, and you can meet the study’s safety and blood/organ requirements.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06176885RecruitingPhase 2
Immunotherapy plus chemo and targeted therapy for MSS colorectal cancer
This trial tests adding immunotherapy to standard chemotherapy and targeted therapy for people with metastatic colorectal cancer that is MSS (microsatellite stable) and cannot be removed with surgery. It aims to see if this combination helps shrink tumors and improve outcomes.
Jinhua, ZhejiangAges 18–75 - NCT06207656RecruitingPhase 2
Targeted therapy for BRAF V600E mutated colorectal cancer
This trial tests if combining three targeted drugs (cetuximab, encorafenib, and binimetinib) before surgery can shrink or control cancer in people with a specific BRAF V600E mutation and a stable (MSS) tumor. It focuses on colorectal cancer that is either already able to be removed or could become removable with treatment.
MadridAges 18 years+ - NCT06218810RecruitingPhase 2
Combination therapy for advanced MSS, RAS-mutated colorectal cancer
This trial tests a new combination of three medicines for people with a certain type of advanced colorectal cancer that has not been treated before. It aims to see if adding an immunotherapy drug (Cadonilimab) to standard chemotherapy and a targeted therapy (Bevacizumab) can help shrink tumors and delay disease progression.
ShanghaiAges 18–75
Hear when a new Microsatellite Stable Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Microsatellite Stable Colorectal Cancer trials by city
Studies with a site in or near these metro areas.
Microsatellite Stable Colorectal Cancer trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for microsatellite stable colorectal cancer?
- Yes. Clin2 currently lists 74 recruiting microsatellite stable colorectal cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a microsatellite stable colorectal cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a microsatellite stable colorectal cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Microsatellite Stable Metastatic Colorectal Cancer
- Microsatellite Stable Colorectal Carcinoma
- Metastatic Microsatellite Stable Colorectal Carcinoma
- Microsatellite Instability-High Colorectal Cancer
- Metastatic Colorectal Cancer
- Colorectal Cancer (CRC)
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Colorectal Cancer Screening
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.